Indirubin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Indirubin 是一种有效的细胞周期蛋白依赖性激酶和 GSK-3β 抑制剂，IC50 约为 5 uM 和 0.6 uM。

Indirubin is a potent and selective CDK inhibitor. Indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases. Indirubin has been used to treat the symptoms of leukemia. Further biological explorations revealed the ability of indirubin to bind cyclin-dependent kinases and 6-bromoindirubin, extracted from mollusks, to bind glycogen synthase kinase-3. Studies have shown that Indirubin can help keep cancer cells from reproducing in rats. Indirubin also appears to reduce inflammation by inhibiting part of the immune response.(In Vitro):Indirubin (Couroupitine B) significantly inhibits Td-EC proliferation, migration, invasion, and angiogenesis.(In Vivo):Indirubin (Couroupitine B) (12.5 mg/kg, 25 mg/kg; intraperitoneal injected; once a day for 14 days) may reduce the pathological alterations in a dose-dependent manner.

Indirubin (Couroupitine B) significantly inhibits Td-EC proliferation, migration, invasion, and angiogenesis.Cell Proliferation Assay Cell Line:Human umbilical vein endothelial cells (HUVEC) line; tumor-derived endothelial cells (Td-EC).Concentration:5, 10μMIncubation Time:24, 48, 72 hours Result:Inhibited Td-EC proliferation in a dose- and time-dependent manner. Cell Invasion Assay Cell Line:Human umbilical vein endothelial cells (HUVEC) line; tumor-derived endothelial cells (Td-EC).Concentration:5μM Incubation Time:overnight Result:Inhibited Td-EC migration, invasion, and angiogenesis.

Indirubin (Couroupitine B) (12.5 mg/kg, 25 mg/kg; intraperitoneal injected; once a day for 14 days) may reduce the pathological alterations in a dose-dependent manner. Animal Model:Male mice (C57BL/6) Dosage:12.5 mg/kg, 25 mg/kg Administration:Indirubin (12.5 mg/kg, 25 mg/kg; intraperitoneal injected; once a day for 14 days)Result:Attenuated alterations of lung structure induced by BLM.

Indirubin | C.I. 73200, Couroupitine B, NSC 105327

Others

Other Targets

GSK-3β , CDK2/CyclinA , CDK5/p35 , CDK1/CyclinB , C-Raf

Cancer

——

479-41-4

262.26

C16H10N2O2

>98% (HPLC)

DMSO : ≥ 41 mg/mL; 156.33 mM

C1=CC=C2C(=C1)/C(=C\3/C(=O)C4=CC=CC=C4N3)/C(=O)N2

3-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-2H-indol-2-one

(-20℃)

With Ice Pack

≥ 2 years